TearExo Inc. has developed a research platform that utilizes tear fluid for the detection of cancer, providing a non-invasive alternative to traditional blood tests. This approach simplifies specimen collection, reduces appointment-related barriers, and enhances patient self-management in cancer screening.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional cancer detection methods often rely on invasive procedures like blood tests, which can be uncomfortable for patients and require specialized medical settings. These methods may also present barriers to frequent screening and early detection due to appointment requirements and patient discomfort.
Solution
TearExo is developing a non-invasive cancer detection platform that utilizes tear fluid as a diagnostic medium. This approach simplifies sample collection, reduces the need for specialized medical personnel, and enhances patient self-management in cancer screening. The TearExo method aims to lower the barriers to testing, promote early detection, and improve patient outcomes through a more accessible and comfortable screening process.
Target Audience
The primary target audience includes individuals at risk of cancer, healthcare providers seeking non-invasive diagnostic tools, and researchers in the field of cancer detection.
Features
- Non-invasive cancer detection using tear fluid samples
- Simplified sample collection process for patient convenience
- Potential for self-administered sample collection and at-home testing
- Early detection capabilities for improved treatment outcomes